(Q42755164)

6 November 2017

title

DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma (English)

1 reference

6 November 2017

1 reference

Ji-Youn Han

1

1 reference

6 November 2017

Kyong-Ah Yoon

2

1 reference

6 November 2017

Jae Hee Park

3

1 reference

6 November 2017

Young Joo Lee

4

1 reference

6 November 2017

Geon Kook Lee

5

1 reference

6 November 2017

Jong Hee Han

6

1 reference

6 November 2017

Sung Jin Yoon

7

1 reference

6 November 2017

Tak Yun

8

1 reference

6 November 2017

Heung Tae Kim

9

1 reference

6 November 2017

Jin Soo Lee

10

1 reference

6 November 2017

language of work or name

English

0 references

publication date

24 January 2011

1 reference

6 November 2017

1 reference

6 November 2017

volume

117

1 reference

6 November 2017

issue

14

1 reference

6 November 2017

page(s)

3201-3208

1 reference

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

6 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

Effects on sister chromatid exchange frequency of polymorphisms in DNA repair gene XRCC1 in smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

Effects of cigarette smoking, XRCC1 genetic polymorphisms, and age on basal DNA damage in human blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

DNA repair and survival in lung cancer--the two faces of Janus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

7 January 2021

The 399Gln polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

7 January 2021

Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

7 January 2021

ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25863

7 January 2021

Identifiers

DOI

10.1002/CNCR.25863

1 reference

6 November 2017

1 reference